1. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. М., 2010.
2. Fernandes PB, Hardy DJ. Comparative in vitro potencies of nine new macrolides. Drugs Exp Clin Res 1988; 14 (7): 445–51.
3. Michelinaki M, Mamos P, Coutsogeorgopoulos C, Kalpaxis DL. Aminoacyl and peptidyl analogs of chloramphenicol as slow-binding inhibitors of ribosomal peptidyltransferase: a new approach for evaluating their potency. Mol Pharmacol 1997; 51: 139–46.
4. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999; 37 (5): 385–98.
5. Visalli MA, Jacobs MR, Appelbaum PC. Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromucin compared with susceptibilities of erithromycin, azithromycin, clarythromycin, roxithromycin, and clindamycin. Antimicrob Agents Chemother 1997; 41 (9): 1867–70.
6. Chien S-M et al. Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group. Chest 1993; 103 (3): 697–701.
7. Noreddin AM, El-Khatib WF, Aolie J et al. Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumonia. Int J Infect Dis 2009; 13 (4): 483–7.
8. Fujiki R, Rikimaru T, Aizawa H, Kawayama T. Clinical efficacy of oral clarithromycin monotherapy in patients with mild or moderate community-acquired pneumonia. Jpn J Antibiot 2003; 56 (6): 712–8.
9. Pişkin N, Aydemir H, Oztoprak N et al. Factors effecting the duration of hospitalization and mortality in patients with community-acquired pneumonia. Mikrobiyol Bul 2009; 43 (4): 597–606.
10. Miyashita N, Kawai Y, Akaike H et al. Transmission of macrolide-resistant Mycoplasma pneumoniae within a family. J Infect Chemother 2013. [Epub ahead of print]
11. Viasus D, Di Yacovo S, Garcia-Vidal C et al. Community-acquired Legionella pneumophila pneumonia: a single-center experience with 214 hospitalized sporadic cases over 15 years. Medicine (Baltimore) 2013; 92 (1): 51–60.
12. Tré-Hardy M, Traore H, El Manssouri N et al. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2009; 34 (4): 370–4.
13. Dicicco M, Neethirajan S, Singh A, Weese JS. Efficacy of clarithromycin on biofilm formation of methicillin-resistant Staphylococcus pseudintermedius. BMC Vet Res 2012; 8: 225. doi: 10.1186/1746-6148-8-225.
14. Uemura Y, Qin L, Gotoh K et al. Comparison study of single and concurrent administrations of carbapenem, new quinolone, and macrolide against in vitro nontypeable Haemophilus influenzae mature biofilms. J Infect Chemother 2013. [Epub ahead of print]
15. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008; 31 (1): 12–20.
16. Amado-Rodríguez L, González-López A, López-Alonso I et al. Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury. Respir Res 2013; 14 (1): 52. [Epub ahead of print]
17. Jouneau S, Kerjouan M, Caulet-Maugendre S et al. Clarithromycin stops lung function decline in airway-centered interstitial fibrosis. Respiration 2013; 85 (2): 156–9.
18. Takahashi E, Kataoka K, Indalao IL et al. Oral clarithromycin enhances airway immunoglobulin A (IgA) immunity through induction of IgA class switching recombination and B-cell-activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus. J Virol 2012; 86 (20): 1024–34.
19. Kitano M, Ishinaga H, Shimizu T et al. Effects of clarithromycin and dexamethasone on mucus production in isografted rat trachea. Pharmacology 2011; 87 (1–2): 56–62.
20. Macleod C et al. Mucolytical effect of clarithromycin once a day in chronic bronchitis. Abstracts of 3rd European Congress of Chemotherapy (ECC), May 7–10, 2000; Madrid, Spain. Abstract T242.

А.А.Визель, И.Ю.Визель, Э.Д.Гизатуллина

Кафедра фтизиопульмонологии ГБОУ ВПО Казанский государственный медицинский университет Минздрава РФ